Therapeutic strategies in patients with acute myeloid leukemia (AML) have not changed significantly over the last decades. Appropriate strategies are ultimately driven by the assessment of patients' fitness to define suitability for intensive induction chemotherapy, which produces high initial remission rates but, increased likelihood of relapse. Old/unfit AML patients still represent an urgent and unmet therapeutic need. Epigenetic deregulation represents a strategic characteristic of AML pathophysiology whereby aberrant gene transcription provides an advantage to leukemic cell survival. Efforts to re-establish impaired epigenetic regulation include hypomethylating agents and histone deacetylase inhibitors (HDACi).

Morabito, F.g., Voso, M.t., Hohaus, S., Gentile, M., Vigna, E., Recchia, A., et al. (2016). Panobinostat for the treatment of acute myelogenous leukemia. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 25(9), 1117-1131 [10.1080/13543784.2016.1216971].

Panobinostat for the treatment of acute myelogenous leukemia

MORABITO, FEDERICO GIUSEPPE;VOSO, MARIA TERESA;GENTILE, MARIA;LO COCO, FRANCESCO;
2016-01-01

Abstract

Therapeutic strategies in patients with acute myeloid leukemia (AML) have not changed significantly over the last decades. Appropriate strategies are ultimately driven by the assessment of patients' fitness to define suitability for intensive induction chemotherapy, which produces high initial remission rates but, increased likelihood of relapse. Old/unfit AML patients still represent an urgent and unmet therapeutic need. Epigenetic deregulation represents a strategic characteristic of AML pathophysiology whereby aberrant gene transcription provides an advantage to leukemic cell survival. Efforts to re-establish impaired epigenetic regulation include hypomethylating agents and histone deacetylase inhibitors (HDACi).
2016
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
NVP-LBH-589; Panobinostat; acute myeloid leukemia; high-risk myelodysplastic syndromes; histone deacetylase inhibitors; therapy
Morabito, F.g., Voso, M.t., Hohaus, S., Gentile, M., Vigna, E., Recchia, A., et al. (2016). Panobinostat for the treatment of acute myelogenous leukemia. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 25(9), 1117-1131 [10.1080/13543784.2016.1216971].
Morabito, Fg; Voso, Mt; Hohaus, S; Gentile, M; Vigna, E; Recchia, A; Iovino, L; Benedetti, E; LO COCO, F; Galimberti, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/160421
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 23
social impact